Answers are grounded in this paper and cite their sources.
Sickle cell disease (SCD) is characterized by hemoglobin S polymerization and diverse red blood cell (RBC) abnormalities that impair microvascular blood flow. The endpoints of the majority of SCD clinical trials include acute pain complications, hemoglobin levels, and markers of hemolysis. Unfortunately, these outcomes do not directly establish whether a therapy normalizes RBC function. We review the role of hemorheological testing in evaluating established, investigational, and potentially curative SCD therapies, and describe the major determinants of abnormal blood flow in SCD, including whole blood viscosity (WBV), RBC deformability, hypoxia-induced sickling, cellular adhesion, and RBC density. Experiences with senicapoc, crizanlizumab, and voxelotor demonstrate how improvement in a single biological or hematologic parameter may fail to establish overall clinical benefit and underscore the need for multimodal functional assessment. Rheological testing may also permit more informative comparisons across hematopoietic stem cell transplantation and gene therapy approaches, for which conventional definitions of a cure remain incomplete. With further analytical standardization and prospective clinical validation, integrated RBC functional profiles could support mechanism-based patient selection, assess treatment response, and identify deterioration before overt acute pain complications or progressive organ injury. Predictive and early detection of clinical deterioration remain investigational. Incorporating rheology into SCD trials may therefore strengthen therapeutic evaluation and support investigation of more individualized clinical care.
No takes yet. Share an insight, caveat, or question.
Aliche et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: